IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-49875-w.html
   My bibliography  Save this article

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer

Author

Listed:
  • Yi Zhang

    (George Washington University School of Medicine and Health Sciences)

  • Shuyan Zhou

    (George Washington University School of Medicine and Health Sciences)

  • Yan Kai

    (George Washington University School of Medicine and Health Sciences)

  • Ya-qin Zhang

    (National Center for Advancing Translational Sciences (NCATS), National Institutes of Health)

  • Changmin Peng

    (George Washington University School of Medicine and Health Sciences)

  • Zhuqing Li

    (George Washington University School of Medicine and Health Sciences)

  • Muhammad Jameel mughal

    (George Washington University School of Medicine and Health Sciences)

  • Belmar Julie

    (Siteman Cancer Center)

  • Xiaoyan Zheng

    (George Washington University School of Medicine and Health Sciences)

  • Junfeng Ma

    (Georgetown University Medical Center)

  • Cynthia X. Ma

    (Washington University School of Medicine)

  • Min Shen

    (National Center for Advancing Translational Sciences (NCATS), National Institutes of Health)

  • Matthew D. Hall

    (National Center for Advancing Translational Sciences (NCATS), National Institutes of Health)

  • Shunqiang Li

    (Siteman Cancer Center)

  • Wenge Zhu

    (George Washington University School of Medicine and Health Sciences)

Abstract

Cyclin-dependent kinases 4 and 6 (CDK4/6) play a pivotal role in cell cycle and cancer development. Targeting CDK4/6 has demonstrated promising effects against breast cancer. However, resistance to CDK4/6 inhibitors (CDK4/6i), such as palbociclib, remains a substantial challenge in clinical settings. Using high-throughput combinatorial drug screening and genomic sequencing, we find that the microphthalmia-associated transcription factor (MITF) is activated via O-GlcNAcylation by O-GlcNAc transferase (OGT) in palbociclib-resistant breast cancer cells and tumors. Mechanistically, O-GlcNAcylation of MITF at Serine 49 enhances its interaction with importin α/β, thus promoting its translocation to nuclei, where it suppresses palbociclib-induced senescence. Inhibition of MITF or its O-GlcNAcylation re-sensitizes resistant cells to palbociclib. Moreover, clinical studies confirm the activation of MITF in tumors from patients who are palbociclib-resistant or undergoing palbociclib treatment. Collectively, our studies shed light on the mechanism regulating palbociclib resistance and present clinical evidence for developing therapeutic approaches to treat CDK4/6i-resistant breast cancer patients.

Suggested Citation

  • Yi Zhang & Shuyan Zhou & Yan Kai & Ya-qin Zhang & Changmin Peng & Zhuqing Li & Muhammad Jameel mughal & Belmar Julie & Xiaoyan Zheng & Junfeng Ma & Cynthia X. Ma & Min Shen & Matthew D. Hall & Shunqia, 2024. "O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49875-w
    DOI: 10.1038/s41467-024-49875-w
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-49875-w
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-49875-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Luigi Formisano & Yao Lu & Alberto Servetto & Ariella B. Hanker & Valerie M. Jansen & Joshua A. Bauer & Dhivya R. Sudhan & Angel L. Guerrero-Zotano & Sarah Croessmann & Yan Guo & Paula Gonzalez Ericss, 2019. "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer," Nature Communications, Nature, vol. 10(1), pages 1-14, December.
    2. Kaushal Asrani & Juhyung Woo & Adrianna A. Mendes & Ethan Schaffer & Thiago Vidotto & Clarence Rachel Villanueva & Kewen Feng & Lia Oliveira & Sanjana Murali & Hans B. Liu & Daniela C. Salles & Brando, 2022. "An mTORC1-mediated negative feedback loop constrains amino acid-induced FLCN-Rag activation in renal cells with TSC2 loss," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    3. Hatice U. Osmanbeyoglu & Fumiko Shimizu & Angela Rynne-Vidal & Direna Alonso-Curbelo & Hsuan-An Chen & Hannah Y. Wen & Tsz-Lun Yeung & Petar Jelinic & Pedram Razavi & Scott W. Lowe & Samuel C. Mok & G, 2019. "Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers," Nature Communications, Nature, vol. 10(1), pages 1-12, December.
    4. Carla L. Alves & Sidse Ehmsen & Mikkel G. Terp & Neil Portman & Martina Tuttolomondo & Odd L. Gammelgaard & Monique F. Hundebøl & Kamila Kaminska & Lene E. Johansen & Martin Bak & Gabriella Honeth & A, 2021. "Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    5. Carla L. Alves & Sidse Ehmsen & Mikkel G. Terp & Neil Portman & Martina Tuttolomondo & Odd L. Gammelgaard & Monique F. Hundebøl & Kamila Kaminska & Lene E. Johansen & Martin Bak & Gabriella Honeth & A, 2021. "Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer," Nature Communications, Nature, vol. 12(1), pages 1-1, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mimi Zhang & Sungsoo Kim & Hee Won Yang, 2023. "Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    2. Marta Palafox & Laia Monserrat & Meritxell Bellet & Guillermo Villacampa & Abel Gonzalez-Perez & Mafalda Oliveira & Fara Brasó-Maristany & Nusaibah Ibrahimi & Srinivasaraghavan Kannan & Leonardo Mina , 2022. "High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer," Nature Communications, Nature, vol. 13(1), pages 1-20, December.
    3. R. C. Coombes & P. D. Badman & J. P. Lozano-Kuehne & X. Liu & I. R. Macpherson & I. Zubairi & R. D. Baird & N. Rosenfeld & J. Garcia-Corbacho & N. Cresti & R. Plummer & A. Armstrong & R. Allerton & D., 2022. "Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    4. Jorge Gómez Tejeda Zañudo & Romualdo Barroso-Sousa & Esha Jain & Qingchun Jin & Tianyu Li & Jorge E. Buendia-Buendia & Alyssa Pereslete & Daniel L. Abravanel & Arlindo R. Ferreira & Eileen Wrabel & Ka, 2024. "Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    5. Wei Zhou & Wenxi Wang & Yuxin Liang & Ruibin Jiang & Fensheng Qiu & Xiying Shao & Yang Liu & Le Fang & Maowei Ni & Chenhuan Yu & Yue Zhao & Weijia Huang & Jiong Li & Michael J. Donovan & Lina Wang & J, 2023. "The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer," Nature Communications, Nature, vol. 14(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49875-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.